FMP
Qualigen Therapeutics, Inc.
QLGN
NASDAQ
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
3.1 USD
0.04 (1.29%)
Historical Prices
From:
To:
About
ceo
Mr. Kevin A. Richardson II
sector
Healthcare
industry
Biotechnology
website
https://www.qualigeninc.comexchange
NASDAQ
Description
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in...
CIK
0001460702
ISIN
US74754R2022
CUSIP
74754R103
Address
2042 Corte Del Nogal
Phone
760 918 9165
Country
US
Employee
4
IPO Date
Jun 23, 2015
Financial Statement
Earnings
QLGN Financial Summary
CIK
0001460702
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
74754R103
ISIN
US74754R2022
Country
US
Price
3.1
Beta
0.11
Volume Avg.
48.68k
Market Cap
2.28M
Shares
-
52-Week
2.96-29.45
DCF
-0.18
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-
P/B
-
Website
https://www.qualigeninc.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest QLGN News
InvestorPlace
Jul 15, 2024
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today?
Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%.
InvestorPlace
Jul 12, 2024
Why Is Qualigen (QLGN) Stock Up 141% Today?
Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual interest rate.
InvestorPlace
Jul 8, 2024
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?
Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more than 59% higher during normal trading hours.
GlobeNewsWire
Mar 15, 2023
Qualigen Therapeutics to Present Five Posters at the America...
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Confer...
GlobeNewsWire
Jun 14, 2022
Qualigen Therapeutics to Present at BIO International Conven...
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.
GlobeNewsWire
May 20, 2022
Qualigen Therapeutics to Present at the H.C. Wainwright Glob...
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hote...
GlobeNewsWire
May 10, 2022
Qualigen Therapeutics' Partner NanoSynex to Present Technolo...
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold
PennyStocks
Apr 12, 2022
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
